Stockhead on MSN1d
Crucible: This rare blood disease tackler plans to hit investors with its best shotThe myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...
The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback